Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + acarbose + pioglitazone in incipient type 2 diabetes mellitus
ChiCTR2100044110Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of metformin, acarbose and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Fasting blood glucose, Glycated hemoglobin (HbA1c) and 5 more. Started Jan 2021; status: recruiting.
02
Drugs
metforminacarbosepioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100044110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044110.